These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Massi D, Franchi A, Ketabchi S, Paglierani M, Pimpinelli N, Santucci M. Hum Pathol; 2003 Jan; 34(1):80-8. PubMed ID: 12605370 [Abstract] [Full Text] [Related]
6. Role of matrix metalloproteinases in melanoma cell invasion. Hofmann UB, Houben R, Bröcker EB, Becker JC. Biochimie; 2005 Jan; 87(3-4):307-14. PubMed ID: 15781317 [Abstract] [Full Text] [Related]
7. Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Daja MM, Niu X, Zhao Z, Brown JM, Russell PJ. Prostate Cancer Prostatic Dis; 2003 Jan; 6(1):15-26. PubMed ID: 12664060 [Abstract] [Full Text] [Related]
12. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Bode W, Maskos K. Biol Chem; 2003 Jun; 384(6):863-72. PubMed ID: 12887053 [Abstract] [Full Text] [Related]
13. Matrix metalloproteinases and their tissue inhibitors in the developing neonatal mouse uterus. Hu J, Zhang X, Nothnick WB, Spencer TE. Biol Reprod; 2004 Nov; 71(5):1598-604. PubMed ID: 15240428 [Abstract] [Full Text] [Related]